| Literature DB >> 35443726 |
Einar Smith1, Ulrika Ericson2, Sophie Hellstrand2, Marju Orho-Melander2, Peter M Nilsson2,3, Céline Fernandez2, Olle Melander2,3, Filip Ottosson2,4.
Abstract
BACKGROUND: The global burden of cardiovascular disease and type 2 diabetes could be decreased by improving dietary factors, but identification of groups suitable for interventional approaches can be difficult. Reporting of dietary intake is prone to errors, and measuring of metabolites has shown promise in determining habitual dietary intake. Our aim is to create a metabolic signature that is associated with healthy eating and test if it associates with type 2 diabetes and coronary artery disease risk.Entities:
Keywords: Coronary artery disease; Dietary biomarker; Metabolomics; Nutrition; Type 2 diabetes
Mesh:
Substances:
Year: 2022 PMID: 35443726 PMCID: PMC9022292 DOI: 10.1186/s12916-022-02326-z
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 11.150
Baseline study characteristics
| Malmö Offspring Study (MOS) | Malmö Diet and Cancer (MDC) | Malmö Preventive Project (MPP) | |
|---|---|---|---|
| Participants ( | 1538 | 2521 | 880/701a |
| Dietary data | Yes | Yes | No |
| Age (years) | 40.4 (13.9) | 57.4 (6.0) | 69.5 (6.1) |
| Sex (% female) | 54.2% | 59.5% | 28.6% |
| LDL (mmol L−1) | 3.13 (0.93) | 4.13 (0.96) | 3.78 (0.98) |
| HDL (mmol L−1) | 1.64 (0.48) | 1.42 (0.37) | 1.36 (0.41) |
| TG (mmol L−1) | 1.09 (0.67) | 1.23 (0.57) | 1.24 (0.63) |
| Glucose (mmol L−1) | 5.49 (1.00) | 4.90 (0.43) | 5.55 (0.59) |
| BMI (kg m−2) | 25.6 (4.5) | 25.3 (3.7) | 27.1 (4.3) |
| Systolic blood pressure (mm Hg) | 117.6 (15.6) | 140.6 (18.5) | 146.4 (21.5) |
| Current smoker | 32.8% | 28.1% | 21.4% |
| Anti-hypertensive treatment | 8.7% | 11.3% | 39.9% |
Values are displayed as mean (SD) or percentages
BMI Body mass index, LDL LDL cholesterol, HDL HDL cholesterol, TG Triglycerides, CAD Coronary artery disease
aThe MPP cohorts had 880 participants included in the CAD nested case control study and 701 included in the type 2 diabetes nested case control study
Fig. 1Metabolic signature model. A The 25 metabolites with the strongest influence on the component in the metabolic signature. B Association with the metabolic signature and health-conscious food pattern in the validation cohort in MOS. C Association with the metabolic signature and the health conscious food pattern in MDC. DMGV, dimethylguanidino valerate
Fig. 2Kaplan–Meier curves. Individuals in MDC split into five quintiles depending on metabolic signature levels. p, p value calculated using log rank test
The association between the metabolic signature and future cardiometabolic disease risk in MDC and MPP
| Model | Person years at risk | Hazard ratio (HR) | |||
| Incident T2D | 1 | 54508 | 322 | 0.58 (0.52–0.65) | 2E− 22 |
| Incident T2D | 2 | 54508 | 322 | 0.58 (0.52–0.66) | 3E− 18 |
| Incident T2D | 3 | 54508 | 322 | 0.73 (0.63–0.83) | 3E− 06 |
| Incident CAD | 1 | 55463 | 303 | 0.73 (0.65–0.82) | 9E− 08 |
| Incident CAD | 2 | 55463 | 303 | 0.87 (0.77–0.99) | 0.03 |
| Incident CAD | 3 | 55463 | 303 | 0.94 (0.82–1.07) | 3 |
| Model | Odds ratio (OR) | ||||
| Incident T2D | 1 | 701 | 203 | 0.53 (0.44–0.63) | 2E− 11 |
| Incident T2D | 2 | 701 | 203 | 0.54 (0.44–0.65) | 1E− 09 |
| Incident T2D | 3 | 701 | 203 | 0.70 (0.55–0.88) | 0.003 |
| Incident CAD | 1 | 880 | 382 | 0.78 (0.68–0.89) | 4E− 4 |
| Incident CAD | 2 | 880 | 382 | 0.86 (0.74–1.00) | 0.06 |
| Incident CAD | 3 | 880 | 382 | 0.93 (0.78–1.11) | 0.4 |
Results from Cox proportional hazard models in MDC and logistics regressions in MPP associating the metabolic signature with risk for type 2 diabetes and CAD. Model 2 is adjusted for smoking status, age, sex and physical activity and model 3 is adjusted for smoking status, age, sex, physical activity, LDL cholesterol, HDL cholesterol, glucose, triglycerides, body mass index, systolic blood pressure, and treatment of anti-hypertensive medicine. In MDC, model 2 and 3 was additionally adjusted for alcohol intake
The odds rations and hazard ratios are standardised to 1 SD increment of the metabolic signature
T2D Type 2 diabetes, CAD Coronary artery disease